Pirfenidone
Treatment for Interstitial Lung Disease And Pulmonary Sarcoidosis
Typical Dosage: 2403 mg daily
Effectiveness
65%
Safety Score
40%
Clinical Trials
1
Participants
2.5K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
40
DangerousModerateSafe
Treatment Details
Dosage Range
2403 mg daily
Time to Effect
3-6 months (sustained effect)
Treatment Duration
Lifetime
Evidence Quality
HIGHNumber Needed to Treat (NNT)
9(Treat 9 patients to see 1 additional successful outcome)
Confidence Score
85%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$7,500
Monitoring:$1,500
Side Effect Mgmt:$1,000
Total Annual:$10,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
POORICER
$250,000/QALY
QALYs Gained
0.2
Outcome-Based Costs
Cost per Responder
$18,182
Pirfenidone Outcomes
for Interstitial Lung Disease And Pulmonary Sarcoidosis
Efficacy Outcomes
Overall Effectiveness
+65%
Response Rate
+55%
Common Side Effects
Nausea
+35%
Diarrhea
+25%
Photosensitivity
+15%
Rash
+15%
Liver enzyme elevation
+10%
Active Clinical Trials
No active trials currently recruiting for this treatment
No active trials found in ClinicalTrials.gov